Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640614 · ClinicalTrials.gov registry record · Phase 3
Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy
A Phase 3 study of Contact Dermatitis, sponsored by Allerderm.
- Completed
- Registry status
- Phase 3
- Development phase
- 235
- Enrollment target
- 5
- Study locations
NCT00640614 is a Phase 3 study of Contact Dermatitis that has completed, run by Allerderm. The registered enrollment target is 235 participants, above the 74-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (218% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT00640614, a Phase 3 study of Contact Dermatitis, has completed, sponsored by Allerderm.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 235 participants
- Enrollment target
- 5
- Study locations
Study Summary
We propose an open, prospective, multi-center Phase III study to evaluate the diagnostic performance and safety of seven new T.R.U.E. Test allergens: Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol.Allergen performance and safety will be evaluated in adult patients with suspected contact dermatitis, and in adult patients with a known or suspected sensitization to at least one of the seven allergens.
Conditions Studied
Interventions
- BIOLOGICAL T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Study Locations (5)
Arkansas
- River City Dermatology - Little Rock
Kansas
- American Dermatology Associates - Shawnee Mission
Kentucky
- Dermatology Specialists PSC - Louisville
New York
- Winthrop University Hospital - Mineola
Other
- Odense University Hospital - Odense C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640614
The ClinicalTrials.gov registry entry for NCT00640614 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 74-participant average among 3 other Contact Dermatitis trials with a reported enrollment target (218% higher). The listed sponsor is Allerderm, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Contact Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens is the first listed.
NCT00640614 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arkansas, Kansas, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00640614 about?
NCT00640614 is a clinical study titled "Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy". We propose an open, prospective, multi-center Phase III study to evaluate the diagnostic performance and safety of seven new T.R.U.E. Test allergens: Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol.Allergen p...
What is the current status of trial NCT00640614?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2008-04. Estimated completion is 2009-10.
What conditions does trial NCT00640614 study?
This clinical trial studies the following conditions: Contact Dermatitis.
What interventions are being tested in trial NCT00640614?
The interventions under investigation include: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens (BIOLOGICAL).
Who is sponsoring clinical trial NCT00640614?
This trial is sponsored by Allerderm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00640614 being conducted?
This trial has 5 study locations across Arkansas, Kansas, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contact Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.